{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-oral/management/adults-immunosuppressive-treatment/","result":{"pageContext":{"chapter":{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)","depth":2,"htmlHeader":"<!-- begin field 44192187-c08e-4234-b1f2-e3431a14c994 --><h2>Scenario: Adults (immunosuppressive treatment)</h2><!-- end field 44192187-c08e-4234-b1f2-e3431a14c994 -->","summary":"Covers the management of oral candidiasis in adults who are receiving treatment that may cause immunosuppression, including oral corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs), and chemotherapy and/or radiotherapy.","htmlStringContent":"<!-- begin item 2892f8f2-dced-4c47-bb11-dfd2bf5a763c --><!-- begin field 72111d95-1f62-4e5d-9e10-acbd00879c7c --><p>From age 18 years onwards.</p><!-- end field 72111d95-1f62-4e5d-9e10-acbd00879c7c --><!-- end item 2892f8f2-dced-4c47-bb11-dfd2bf5a763c -->","topic":{"id":"0f1d88eb-55a0-530e-a259-eb14f0dda14a","topicId":"b0c376a4-6364-437c-b2b0-0b37c1f9457c","topicName":"Candida - oral","slug":"candida-oral","lastRevised":"Last revised in September 2019","chapters":[{"id":"18d6ae12-7e70-5db1-bc04-693d5cb239d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5e30b9ac-9bad-5d72-95a0-522910be9b02","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6e1a973-1e09-50e9-884c-3320ada5f64a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e89a359d-f797-5ff2-a94a-511199763a4b","slug":"changes","fullItemName":"Changes"},{"id":"e3aa3dcf-265b-5bf3-8920-86af41a82b81","slug":"update","fullItemName":"Update"}]},{"id":"1c10a9c3-b22e-5e15-9f5e-fd1b321eda87","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2044b7f8-9a22-580a-a6ee-d09f8e57e822","slug":"goals","fullItemName":"Goals"},{"id":"a2a6fc92-6ee5-5340-8de6-99645565cff9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3d375136-1f32-5b18-bfaa-072565762749","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5055e999-d687-5080-a905-6d314ff96a68","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7974345e-7b16-5e65-be63-f0b8a60779ef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19434a87-22cd-57f9-9507-fa3784bc88e9","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52cafe43-224c-5c66-934b-d40eb1b71de5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"372003e6-a514-5b66-8e01-c0c4c24fcf84","slug":"definition","fullItemName":"Definition"},{"id":"6209fe71-2228-5859-966c-9dbcca7da121","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"543a3d8a-2699-5ab1-8d60-91f808bddfdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f317e3a4-4b69-5c95-9d13-c551a893ac44","slug":"complications","fullItemName":"Complications"},{"id":"a19dd915-bb50-52c5-94e7-3c7f215a0ac3","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8b32d0b5-0a06-58dc-9e26-cd5930c9b82e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e6f234d8-47d7-5740-8739-58962c6c3a1c","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"f276724c-839b-5e50-9ed1-f685c12b1c5a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4dbdf8e9-97b5-54f2-8023-94e3da894f99","slug":"children-not-immunocompromised","fullItemName":"Scenario: Children (not immunocompromised)"},{"id":"462896e2-aa8a-5693-80bc-cb11b1d29ef2","slug":"adults-young-people-not-immunocompromised","fullItemName":"Scenario: Adults and young people (not immunocompromised)"},{"id":"10d79010-5f47-51a1-be04-e6086178a3da","slug":"adults-immunosuppressive-treatment","fullItemName":"Scenario: Adults (immunosuppressive treatment)"},{"id":"13250ef8-0c39-5e07-b367-3b38fab47e57","slug":"adults-hiv-positive","fullItemName":"Scenario: Adults (HIV positive)"}]},{"id":"800e543f-aa34-535b-982f-b67228787534","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"50f16582-74d2-54ab-82c2-4d34b643efbd","slug":"miconazole-oral-gel","fullItemName":"Miconazole oral gel"},{"id":"52caf1d3-9e52-581c-aa51-d6c5e0d34239","slug":"nystatin-suspension","fullItemName":"Nystatin suspension"},{"id":"eaecb9ab-d5ac-5b61-b987-ed97a3b933fd","slug":"fluconazole-oral","fullItemName":"Fluconazole - oral"}]},{"id":"9d6aa898-2416-5c14-92f0-effd8eee476e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aefe3a29-b255-5d42-81cf-2ec2c53a1d28","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f1d318f6-b308-52db-a6ef-c314467ec43f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4b0b04f2-6c79-5699-8121-895467604792","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"545d5c41-fb5a-5561-9a76-8cf64fe0b179","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"098d8b0b-527b-57aa-b706-e69ada6b04fd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e055ac7-10af-5a82-b3ff-1d1c789b3c91","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4e3093df-a561-5cba-84a5-99f5890a58a5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"32ef3be0-0861-5c08-932e-c4295def32b8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"adf1777b-06b9-589a-a89b-49a14f20e8c9","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field d5bcdeab-cc26-4a74-91eb-43a50e138a4d --><h3>How should I manage oral candidiasis in an adult who is receiving treatment(s) that may cause immunosuppression?</h3><!-- end field d5bcdeab-cc26-4a74-91eb-43a50e138a4d -->","summary":null,"htmlStringContent":"<!-- begin item eb8c9981-0ade-4ce9-b325-3423e80bfe8a --><!-- begin field 7cd76828-407f-48b2-9a30-6c5ddcaadf31 --><p><strong>Admit the person if:</strong></p><ul><li>There is evidence of <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">systemic illness</a> (candidaemia).</li><li>There is widespread infection (such as oesophageal candidiasis, characterized by difficulty or pain on swallowing, or retrosternal pain).<ul><li>Lower the threshold for admission in people who are markedly immunocompromised.</li></ul></li></ul><p><strong>If the person can be managed in primary care:</strong></p><ul><li><strong>Seek specialist advice before starting antifungal treatment </strong><strong>if the person is:</strong><ul><li>Taking ciclosporin or oral tacrolimus, especially if these drugs are being used to suppress tissue rejection following transplantation.</li><li>Receiving chemotherapy.</li></ul></li><li><strong>For people taking oral corticosteroids or disease-modifying anti-rheumatic drugs</strong> <strong>(DMARDs):</strong><ul><li><strong>If the infection is mild and localized, </strong>prescribe topical treatment for 7 days.<ul><li>Offer miconazole oral gel first-line.</li><li>If miconazole is unsuitable, offer nystatin suspension. </li><li>See the prescribing information sections on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/miconazole-oral-gel/\">Miconazole oral gel</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/nystatin-suspension/\">Nystatin suspension</a> for information on prescribing these treatments.</li></ul></li><li><strong>If the infection is extensive or severe,</strong> consider one of the following options:<ul><li>Prescribe oral fluconazole 50–100 mg a day for 7 days. See the prescribing information section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/\">oral fluconazole</a> for information on prescribing this treatment.</li><li>Seek specialist advice or refer to an oral surgeon.</li></ul></li><li><strong>If there is suspicion that DMARDs are causing marked immunosuppression, </strong>seek specialist advice and ensure blood parameters are being adequately monitored. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/\">DMARDs</a> for more information.</li></ul></li><li><strong>Give appropriate lifestyle advice. </strong>In particular:<ul><li>Advise on good dental hygiene.</li><li>If the person is a smoker, offer advice on smoking cessation. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for detailed information.</li><li>If the person is using an inhaled corticosteroid, advise the following: good inhaler technique; rinsing the mouth with water (or cleaning the teeth) after inhalation, to remove any drug particles; using a spacer device to reduce the impaction of particles in the oral cavity; and stepping down the dose of inhaled corticosteroid when appropriate.<ul><li>See the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/management/corticosteroids-inhaled/#minimizing-adverse-effects\">Minimizing&nbsp;the risks of adverse effects</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-inhaled/\">Corticosteroids - inhaled</a> for more information. </li></ul></li><li>If the person wears dentures, advise them to:<ul><li>Leave the dentures out for at least 6 hours in each 24-hour period to promote healing of the gums. If the gums are inflamed, they may benefit from the dentures being left out for longer.</li><li>Clean dentures by brushing and then soaking them in a disinfectant solution (for example chlorhexidine or hexetidine) overnight. The dentures can be soaked in any solution marketed to sterilize baby's bottles (providing the dentures contain no metal).</li><li>Allow the dentures to air-dry after disinfection — this also kills adherent<em> Candida</em>.</li><li>Brush the mucosal surface regularly with a soft brush.</li><li>See a dentist to correct ill-fitting dentures.</li></ul></li><li>If the person has diabetes,<strong> </strong>review diabetic control and manage accordingly, particularly if there are recurrent episodes of oral candidiasis. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a> for detailed information.<ul><li>For people taking a sulphonylurea (such as gliclazide), be aware of drug interactions with <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/miconazole-oral-gel/\">miconazole</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/#drug-interactions\">fluconazole</a>.</li></ul></li></ul></li><li><strong>Follow up the person after 7 days. </strong>If treatment has not been fully effective despite adequate adherence to treatment:<ul><li><strong>For people receiving topical treatment, </strong>consider:<ul><li>Extending the course of treatment for a further 7 days, <em>or</em></li><li>Switching to nystatin suspension (if miconazole was tried first-line) or oral fluconazole.</li></ul></li><li><strong>For people receiving oral fluconazole:</strong><ul><li>Consider the following: extend the course of fluconazole for a further 7 days and increase the dose to 100 mg per day if 50 mg was initially prescribed (refer to an oral surgeon if the infection persists after this); swab to identify the causative organism; seek specialist advice; or refer to an oral surgeon. </li><li>Use clinical judgement, taking into account the severity of infection (there should be a low threshold for early referral if infection is severe), the level of immunocompromise, and the response to treatment. </li></ul></li></ul></li><li><strong>Also consider referring to an oral surgeon (or seeking specialist advice) if:</strong><ul><li>The person has recurrent episodes of oral candidiasis.</li><li>The person has breakthrough candidal infection while receiving preventive treatment (which may indicate candidal resistance).</li><li>The person has clinical features that preclude management in primary care.</li><li>There is doubt about the diagnosis. </li></ul></li><li><strong>Consider referring for biopsy</strong> people with <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/diagnosis/diagnosis/\">chronic plaque-like oral candidiasis</a> that is unresponsive to treatment, as it carries a risk of malignancy.</li></ul><!-- end field 7cd76828-407f-48b2-9a30-6c5ddcaadf31 --><!-- end item eb8c9981-0ade-4ce9-b325-3423e80bfe8a -->","subChapters":[{"id":"7b963953-b194-5541-a48c-0fe60827936e","slug":"basis-for-recommendation-e35","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c8d0095d-0cc7-4a80-aebd-3131d718d9a6 --><h4>Basis for recommendation</h4><!-- end field c8d0095d-0cc7-4a80-aebd-3131d718d9a6 -->","summary":null,"htmlStringContent":"<!-- begin item e35c9945-03da-4bc4-bdc9-a440e36c6e74 --><!-- begin field ee674cdc-3e1b-450c-a542-b6fdfb677ddb --><p>These recommendations are based on expert opinion in the guideline <em>Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>], review articles on oral infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Ellepola and Samaranayake, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Akpan and Morgan, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Gonsalves et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Su et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Laudenbach and Epstein, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Garcia-Cuesta, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Singh, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Patil, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BMJ, 2017</a>], and a dermatology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Hay and Ashbee, 2010</a>].</p><h5>Admission</h5><ul><li>This recommendation is based on the fact that systemic/invasive candidiasis is a significant cause of morbidity and mortality, especially in people who are immunocompromised. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">Complications</a> for more information.</li></ul><h5>Seeking specialist advice before starting antifungal treatment in people taking ciclosporin or tacrolimus</h5><ul><li>This recommendation is based on the fact that fluconazole increases the plasma concentrations of these drugs. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/prescribing-information/fluconazole-oral/#drug-interactions\">Drug interactions</a> for more information.</li></ul><h5>Seeking specialist advice before starting antifungal treatment in people receiving chemotherapy</h5><ul><li>This recommendation is based on the fact that people receiving chemotherapy are likely to be taking drugs that cause complex interactions which may be difficult to manage in primary care.</li><li>Management of people with marked immunosuppression caused by chemotherapy or radiotherapy is primarily carried out in secondary care under specialist direction. If there is any doubt about management, referral should be considered or specialist advice sought, as the consequences of widespread or invasive candidiasis are particularly serious in people who are immunosuppressed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>].</li></ul><h5>Antifungal treatments</h5><ul><li><strong>Miconazole</strong> has a broad spectrum of activity against fungal and yeast species [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>].<ul><li>There is a lack of published evidence from randomized controlled trials (RCTs) to support the use of miconazole oral gel in people with oral candidiasis who are receiving immunosuppressant drugs. However, it is reasonable to suppose it is effective based on historical use, clinical experience, and extrapolation of data in other groups.</li></ul></li><li><strong>Nystatin</strong> suspension is not absorbed from the gastrointestinal tract and is applied locally to the mouth for treating local fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. <ul><li>It has been used as an active control in people receiving treatment for cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Worthington et al, 2010</a>], and has generally not<em> </em>been found to be as effective as other antimycotic drugs. It is therefore not suitable as a first-line treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>].</li></ul></li><li><strong>Fluconazole</strong> has a broad range of antifungal activity, including against <em>Candida</em> species [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>]. It is suitable for people on immunosuppressant drugs who have extensive or severe candidiasis. It is systemically absorbed, which is an advantage for widespread candidal infection.</li></ul><h5>Seeking specialist advice if there is suspicion that disease-modifying anti-rheumatic drugs (DMARDs) are causing marked immunosuppression</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li></ul><h5>Lifestyle advice</h5><ul><li>These recommendations are based on the fact that poor dental hygiene, inhaled corticosteroids, the use of dentures, smoking, and diabetes are also risk factors for oral candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/causes-risk-factors/\">Risk factors</a> for more information.<ul><li>In addition for dentures:<ul><li>Expert opinion in review articles is that chlorhexidine is an antiseptic with a broad-spectrum activity, including antimycotic activity against <em>Candida</em> species. It can be used as an effective disinfectant for dentures, and it inhibits adhesion of <em>Candida</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Ellepola and Samaranayake, 2001</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Garcia-Cuesta, 2014</a>].</li><li>A small, open-label, comparative RCT in 61 people found that twice-daily rinses with the antiseptic hexetidine resulted in a significant reduction in the amount of <em>C. albicans </em>present in saliva, compared with pretreatment levels (no control group was included) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Koray et al, 2005</a>].</li><li>Expert opinion in a guideline is that for the management of denture-related candidiasis, disinfection of the denture, in addition to antifungal treatment, is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Pappas, 2016</a>].</li></ul></li><li>In addition for diabetes, most experts agree that good control of blood glucose is important in the long-term management of oral candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Soysa et al, 2006</a>]. This will also have other wide-reaching benefits.</li></ul></li></ul><h5>Follow up and managing treatment failure</h5><ul><li>Oral candidiasis is a serious cause of <a class=\"topic-reference internal-reference\" href=\"/topics/candida-oral/background-information/complications/\">morbidity and mortality</a> in people who are immunosuppressed, and it is reasonable to ensure treatment has been satisfactory and complications have not developed.</li><li>Expert opinion in a review article is that if initial treatment is not fully effective, extending treatment duration is a reasonable option before expert advice or referral are sought, provided deterioration has not occurred [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Samaranayake et al, 2009</a>]. CKS recommends using clinical judgement to decide whether to give another course of fluconazole, swab to identify the causative organism, seek specialist advice, or refer to secondary care, taking into account the severity of infection, the level of immunocompromise, and the response to treatment. <ul><li>The recommendation to consider swabbing is based on expert opinion in a review article, which states that microbiological techniques are required when the clinical diagnosis needs to be confirmed, for establishing a differential diagnosis, and in cases characterized by resistance to antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>].</li></ul></li><li>Advice in the BNF is that the dose and duration of fluconazole may be increased in people with unusually difficult candidal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>].</li></ul><h5>Referral or seeking specialist advice</h5><ul><li>The BNF recommends referral for investigation if candidal infection fails to respond to 1–2 weeks of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. Other referral criteria are based on what CKS considers to be good clinical practice. </li><li>Expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Coronado-Castellote, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Singh, 2014</a>] and the BNF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>] is that biopsies are indicated in people with hyperplastic candidiasis, due to the increased risk of malignancy.</li></ul><h5>Treatments not recommended </h5><ul><li><strong>Miconazole mucoadhesive buccal tablets </strong>are licensed for the treatment of oropharyngeal candidiasis in immunocompromised people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. However, they are considerably more expensive than miconazole oral gel and are not currently recommended by the Scottish Medicines Consortium [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Scottish Medicines Consortium, 2011</a>]. For these reasons, CKS does not recommend its use in primary care.</li><li><strong>Oral itraconazole </strong>should be reserved for cases of fluconazole-resistant candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">BNF 72, 2016</a>]. Specialist advice should be obtained before initiating itraconazole therapy because of the increased risk of drug interactions and adverse effects.</li><li><strong>Oral ketoconazole </strong>should no longer be prescribed for the treatment of fungal infections as the risk of liver damage outweighs the benefits. For this reason, the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has suspended its marketing authorisation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">MHRA, 2013</a>]. See the <a href=\"http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON297530\" data-hyperlink-id=\"69d3a7ca-7081-4075-9489-a99201477833\">MHRA website</a> for more information.</li><li><strong>Oral amphotericin </strong>is not recommended as there is a lack of trial evidence of efficacy in the treatment of oral candidiasis. It is sometimes used as an adjunct to other systemic antimycotic drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-oral/references/\">Laudenbach and Epstein, 2009</a>].</li></ul><!-- end field ee674cdc-3e1b-450c-a542-b6fdfb677ddb --><!-- end item e35c9945-03da-4bc4-bdc9-a440e36c6e74 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}